Covalent Inhibitor Selectivity Profiling Service

Evaluate target engagement, off-target burden, analog series behavior, and proteome-wide selectivity using LC-MS/MS-based chemoproteomics.

Covalent inhibitor selectivity profiling helps drug discovery teams evaluate target engagement, off-target burden, analog series behavior, and proteome-wide selectivity using LC-MS/MS-based chemoproteomics. At Creative Proteomics, we support compound-fit review, competitive profiling, QC-guided interpretation, and review-ready deliverables for covalent inhibitor programs.

Key Advantages:

Profile proteome-wide inhibitor selectivity.
Compare target and off-target engagement.
Rank analog series for optimization.
Review residue evidence where supported.
Receive raw and processed data tables.

Discuss Your Profiling Project

Covalent inhibitor selectivity profiling service overview showing compounds, biological samples, LC-MS/MS, heatmap, and target off-target outputs.

Profiling Capabilities Use Cases Workflow Sample Demo Deliverables Comparison Strategy Case Study FAQ References Disclaimer

Covalent Inhibitor Profiling for Selectivity, Target Engagement, and Off-Target Risk

Covalent inhibitors can be powerful tools in drug discovery because they form durable interactions with protein targets. However, the same reactive chemistry that makes them attractive can also create unwanted off-target labeling. A compound may look potent in a biochemical assay but still show broad reactivity across a complex proteome.

Our covalent inhibitor selectivity profiling service is designed to help you move beyond single-assay potency and understand how a compound behaves across a wider protein landscape. Using LC-MS/MS-based chemoproteomics, competitive profiling, and structured data analysis, we help evaluate intended target engagement, off-target burden, analog selectivity, and residue- or peptide-level evidence where the workflow supports it.

What Covalent Inhibitor Selectivity Profiling Measures

A well-designed covalent inhibitor profiling study can help answer several linked questions:

Does the compound engage the intended target?
Does the compound show broad off-target labeling?
Which proteins or protein families are most affected?
Does engagement change with concentration or treatment condition?
Which analogs show cleaner selectivity?
Is there peptide- or residue-level evidence to support a target call?
Which findings should be prioritized for follow-up validation?

For many programs, the most useful output is not a single target name. It is a ranked, review-ready profile showing how each compound behaves across target and off-target proteins under controlled conditions.

Why Potency Alone Is Not Enough for Covalent Drug Discovery

Potency does not always mean selectivity. A highly reactive covalent compound may show strong apparent activity while also labeling many unintended proteins. A less reactive analog may look weaker in one assay but provide a more useful balance between engagement and off-target burden.

Covalent inhibitor profiling helps put potency into context. By looking across a complex proteome, the workflow can help show whether a compound is selectively engaging a small target set or producing broad nonspecific labeling. This is especially important when teams are comparing electrophilic fragments, covalent inhibitor candidates, or analog series during lead optimization.

For related method context, see our Activity-Based Protein Profiling (ABPP-MS) service.

Our Covalent Inhibitor Profiling Capabilities

We designed this service for discovery teams that need practical evidence for compound decisions. We review compound fit, help select the profiling format, process samples through MS-based chemoproteomics workflows, and organize results so they can support target engagement, selectivity, and follow-up planning.

MODE 1

Proteome-Wide Selectivity Profiling

Proteome-wide selectivity profiling helps reveal how a covalent inhibitor behaves beyond a single intended target. Depending on the method design, this may include target and off-target ranking, compound-by-protein heatmaps, concentration-response views, and evidence tables.

Review whether a compound has a narrow engagement profile.
Identify broader off-target patterns that may affect downstream decisions.

MODE 2

Competitive ABPP for Target Engagement

Competitive activity-based protein profiling is especially useful when the compound can be evaluated within a probe-accessible protein space. In this format, a candidate inhibitor competes with an activity-based probe. Reduced probe labeling can indicate compound engagement.

Support target engagement confirmation.
Profile off-target risk within a probe-accessible space.
Compare covalent analogs during optimization.
Connect with our Competitive ABPP service.

MODE 3

Analog Series Comparison

Medicinal chemistry teams often need to compare multiple covalent analogs rather than evaluate a single compound. We can help organize profiling data to show how analogs differ in target engagement, off-target burden, dose-response behavior, and selectivity pattern.

Identify compounds that maintain intended target engagement.
Review which analogs show reduced broad proteome-wide reactivity.
Support analog triage and follow-up experiment design.

MODE 4

Reactive Residue and Site-Level Evidence

Where supported by the probe strategy, enrichment chemistry, peptide coverage, and LC-MS/MS data quality, covalent inhibitor profiling can provide peptide- or residue-level evidence. This can help connect a protein-level hit to a more specific chemical interaction site.

Support reactive cysteine or other chemically addressable residue review.
Clarify expectations during project design.
Connect with our Reactive Residue Profiling service.

MODE 5

Follow-Up Strategy Recommendations

A useful profiling project should help you decide what to do next. Based on the result pattern, we can help identify which targets may need orthogonal validation, which off-targets deserve closer review, and which compounds may be better suited for further optimization.

Plan additional competitive profiling when needed.
Pair findings with pull-down chemoproteomics or thermal stability profiling.
Support purified-target binding assays or functional validation planning.

When to Use Covalent Inhibitor Selectivity Profiling

Covalent inhibitor selectivity profiling is most useful when a compound is active but the selectivity, target engagement, or off-target profile is still uncertain.

When a Covalent Hit Needs Selectivity Review

A covalent hit from a biochemical assay, phenotypic screen, or fragment campaign may need a proteome-wide review before deeper investment. Profiling can help determine whether the compound shows a selective engagement pattern or broad reactivity.

This is especially important for electrophilic hits, clickable analogs, and warhead-containing compounds that may interact with multiple proteins.

When Cellular Activity Does Not Explain the Target

Cellular activity can be difficult to interpret. A compound may produce a strong phenotype, but the active target may not be clear. The observed effect could result from the intended target, one or more off-targets, pathway-level disruption, or general reactivity.

Covalent inhibitor profiling can help connect activity to target engagement and off-target evidence. It can also support broader mechanism-of-action studies when combined with target deconvolution or response profiling.

When Analog Series Need Prioritization

Analog series profiling helps medicinal chemistry teams compare compounds side by side. Instead of ranking analogs only by potency, the data can help compare target engagement strength, off-target signal, concentration behavior, and selectivity pattern.

This can be particularly useful when several analogs appear similarly active in a primary assay but differ in proteome-wide behavior.

When Off-Target Risk Could Stop Progression

Broad off-target labeling can reduce confidence in a covalent inhibitor program. Profiling can help identify compounds with heavy off-target burden and separate them from analogs with cleaner engagement. It can also help flag protein families or specific proteins that may require follow-up review.

For upstream hit work, see our Covalent Fragment Screening service.

Workflow with QC Checkpoints from Compound Intake to Data Delivery

Our workflow follows the project from compound and sample review through final data delivery. Each stage includes both technical execution and QC review so that the final interpretation reflects the compound, sample system, controls, and LC-MS/MS data quality.

Compound and Sample Fit Review

We review compound class, intended target if known, warhead or reactive group, analog series structure, solvent, stock concentration, sample type, comparison groups, probe or enrichment strategy, and required controls.

Treatment Design and Control Setup

We help plan vehicle controls, compound treatment groups, concentration points, analog comparisons, probe controls, and replicate structure.

Live-Cell, Lysate, or Tissue Lysate Preparation

Live-cell profiling is useful when cellular permeability and intact-cell context matter. Lysate profiling supports controlled proteome access. Tissue lysate profiling may help when model-specific biological context is important.

Probe Labeling or Chemoproteomic Enrichment

When competitive ABPP is selected, an activity-based probe is used to measure probe-accessible targets after compound treatment. In other chemoproteomic designs, clickable analogs or affinity handles may support enrichment-based profiling.

LC-MS/MS Acquisition

Prepared samples are analyzed by LC-MS/MS. The acquisition and quantification strategy depends on sample complexity, comparison design, and whether protein-level, peptide-level, or site-level evidence is needed.

Data Filtering and QC Review

After database searching and quantification, we review control behavior, replicate consistency, background signal, off-target burden, and evidence quality.

Final Profiling Report and Decision Notes

The final report is built to support decision-making with ranked target/off-target tables, selectivity heatmaps, concentration-response summaries where included, QC notes, and interpretation comments.

Vertical covalent inhibitor selectivity profiling workflow with QC checkpoints from compound intake to final data report.

The final result should help you answer which compounds show the cleanest selectivity, which targets or off-targets are most important, which analogs should be prioritized, which results require follow-up validation, and which profiling strategy should be used next.

Sample Requirements and Project Intake Checklist

The table below gives planning guidance for common covalent inhibitor profiling inputs. Final requirements depend on the selected workflow, sample type, probe chemistry, and project design.

Sample / Input Type	Recommended Amount / Format	Required Information	Best-Fit Use	QC Checkpoints	Notes
Cultured cells	Reference planning range: 5 × 10⁶ cells for label-free quantitative proteomics; 1 × 10⁷ cells for DIA-style quantitative proteomics	Cell line, treatment design, compound concentration range, timepoint, controls	Live-cell engagement and selectivity profiling	Cell pellet consistency, treatment consistency, labeling or enrichment performance	Cell samples should be washed with pre-chilled PBS, flash-frozen, stored at −80°C, and shipped with dry ice where applicable
Tissue lysate / tissue sample	Reference planning range: soft animal tissue 100 mg for label-free quantitative proteomics and 200 mg for DIA-style quantitative proteomics	Tissue type, group design, storage condition, model or treatment information	Tissue-context profiling	Sample integrity, heterogeneity, protein recovery	Samples should be collected consistently, flash-frozen, stored at −80°C, and protected from repeated freeze-thaw cycles
Trace tissue / limited material	Reference planning range: 30–50 mg general animal tissue for trace DIA-style proteomics	Tissue type, availability, grouping, storage condition	Limited-sample feasibility review	Protein recovery, sample loss risk, LC-MS/MS depth	Technical review is recommended before preparing limited samples
Compound / analog series	Compound list, structures if available, solvent, stock concentration, warhead or reactive group	Compound ID, analog grouping, known activity, known target, solubility notes	Analog ranking and off-target comparison	Compound-fit review, solubility, control design	Provide reactive group and known activity information when available
Probe or clickable analog	Probe class, handle, target class, storage notes	Probe structure or supplier information, expected labeling space	ABPP or chemoproteomic enrichment	Probe control, background signal, enrichment performance	Probe choice defines the measurable chemical space

Before submission, please prepare the compound list and analog grouping, compound structures if available, solvent and stock concentration, known target or pathway information, treatment design and concentration range, sample type and biological model, control groups and replicate plan, probe or enrichment strategy if already selected, and any solubility, toxicity, buffer, or handling concerns.

Representative Demo Results for Covalent Inhibitor Profiling

Representative outputs should help your team understand selectivity and decide what to do next. We usually organize demo-style outputs around three views: selectivity pattern, target engagement trend, and ranked evidence.

Representative covalent inhibitor profiling demo results with selectivity heatmap, dose-response curves, and ranked target off-target table.

Representative covalent inhibitor profiling outputs

Demo 1: Proteome-Wide Selectivity Heatmap

A selectivity heatmap can compare target and off-target signals across vehicle, inhibitor A, inhibitor B, inhibitor C, or an analog series. Rows may represent proteins or protein groups, while columns represent treatment conditions.

Review which compounds show the broadest off-target burden.
Compare clean target engagement patterns across analogs.
Identify off-targets that appear repeatedly across analogs.
Prioritize proteins for follow-up studies.

Demo 2: Dose-Response Target Engagement Curves

When a concentration series is included, selected proteins or sites can be visualized as dose-response engagement curves. These curves can help show whether engagement increases with compound concentration and whether the response appears target-specific or broad.

Review concentration-dependent engagement trends.
Compare proteins that respond at lower concentrations.
Identify analogs with stronger or cleaner engagement.
Flag weak or inconsistent signals.

Demo 3: Ranked Target and Site-Level Evidence Table

A ranked evidence table can combine protein identity, target/off-target status, peptide or site evidence where supported, engagement trend, selectivity flag, and follow-up priority.

Rank top candidate targets.
Review off-targets that may affect compound progression.
Distinguish protein-level evidence from site-supported evidence.
Decide which findings should be validated first.

Bioinformatics Analysis and Deliverables

Covalent inhibitor profiling data can be complex. We organize the deliverables so your team can review the evidence, trace the analysis, and use the results in internal project discussions.

Deliverable	What It Helps You Review
Raw LC-MS/MS files	Primary data archive and reanalysis support
Search result files	Protein and peptide identification review
Protein-level quantified table	Target and off-target ranking
Peptide / site-level evidence table, where applicable	Residue or peptide-supported interpretation
Ranked target / off-target candidate list	Follow-up prioritization
Selectivity heatmap	Visual comparison across compounds or analogs
Dose-response or concentration-response summary, where included	Engagement trend review
QC summary	Replicate behavior, controls, and data quality
Methods and parameter summary	Traceability of analysis settings
Visualization-ready figures	Internal presentation and project review

Optional add-ons can include analog series comparison, dose-response modeling, off-target burden scoring, protein family annotation, pathway or functional enrichment, reactive residue class summary, orthogonal validation recommendations, and custom filtering.
We help translate profiling outputs into practical decisions, such as prioritizing analogs with cleaner selectivity, flagging compounds with broad off-target burden, nominating target proteins for follow-up validation, and supporting mechanism-of-action hypotheses with proteome-wide evidence.
For related broad ABPP data workflows, see Global ABPP (LC-MS/MS).

Covalent Inhibitor Profiling vs Other Target Engagement Methods

Each method answers a different type of question. Covalent inhibitor selectivity profiling is most useful when the project needs proteome-wide target engagement, off-target evidence, analog comparison, and, where supported, residue-level interpretation.

Method	Best-Fit Question	Sample Context	Requires Probe or Compound Modification	Target Engagement Evidence	Off-Target Profiling Ability	Site-Level Evidence Potential	Key Limitation	Best Follow-Up Use
Covalent inhibitor selectivity profiling	Is the compound selective across the proteome?	Live cells, lysates, tissue lysates depending on design	Depends on workflow	Strong for measured chemical space	Strong	Possible where peptide/site data support it	Scope depends on profiling chemistry and sample design	Compound prioritization and off-target review
Competitive ABPP	Does the compound compete within a probe-accessible protein space?	Live cells or lysates	Requires suitable activity-based probe	Strong	Strong within probe-accessible space	Possible	Does not cover proteins outside probe scope	Target engagement and analog ranking
Pull-down chemoproteomics	Which proteins are enriched by a modified compound or probe?	Lysates, cells, or enriched samples	Usually requires handle, clickable analog, or affinity tag	Moderate to strong	Moderate	Sometimes	Compound modification may affect binding	Direct binder enrichment and target ID
Thermal stability profiling	Which proteins show stability changes after compound treatment?	Cells or lysates	No probe required	Indirect stability-based evidence	Moderate	Usually protein-level	Not all engagement causes a stability shift	Orthogonal engagement support
DARTS / LiP-MS	Which proteins change proteolytic sensitivity or structure after ligand exposure?	Lysates or purified systems	No compound modification required	Indirect structural/accessibility evidence	Moderate	LiP-MS may provide region-level evidence	Requires careful proteolysis interpretation	Structural accessibility follow-up
SPR / ITC	What is the affinity, kinetics, or thermodynamics for a purified target?	Purified target	No proteome-wide sample	Strong for purified target	Low	No proteome-wide site map	Not global and requires purified protein	Biophysical validation
Standard quantitative proteomics	Which proteins change in abundance after treatment?	Cells, tissues, fluids	No probe required	Indirect downstream response	Low to moderate	Protein-level abundance	Does not directly measure engagement	Pathway response and MoA context

For orthogonal cellular engagement, covalent inhibitor profiling can be paired with Proteome-wide Thermal Stability Profiling.

How to Choose the Right Profiling Strategy

Choose Live-Cell Profiling When Cellular Context Matters

Live-cell profiling is useful when compound permeability, cellular context, and intact-cell target engagement are central to the question. It is a strong option when cellular activity has already been observed and the goal is to connect that activity with target or off-target evidence.

Cell permeability matters.
Cellular engagement is the key question.
Off-target behavior in intact cells is a concern.
The compound has a cellular phenotype that needs explanation.

For cellular ABPP projects, see Live-cell ABPP.

Choose Lysate Profiling When Controlled Proteome Access Matters

Lysate profiling can be useful when direct compound-proteome exposure is more important than intact-cell context. It can reduce variables related to permeability and metabolism, making it helpful for early analog comparison.

Compound permeability is uncertain.
The goal is controlled proteome comparison.
Analog ranking is the main question.
You want to explore target space before cell-based follow-up.

Choose Competitive ABPP When Probe-Accessible Targets Are Central

Competitive ABPP is a strong fit when the target class, residue space, or protein family can be measured with a suitable activity-based probe. It is particularly useful for comparing engagement and selectivity across covalent inhibitors.

A relevant activity-based probe is available.
Target engagement and off-target profiling are linked.
Site-level evidence may be important.
You need an analog series comparison.

Add Orthogonal Methods When the Question Extends Beyond Probe Competition

No single method answers every question. If the profiling result raises a specific follow-up question, we can help pair it with complementary strategies.

Pull-down chemoproteomics for enrichment-based target identification.
Thermal stability profiling for stability-shift evidence.
Standard quantitative proteomics for downstream pathway response.
SPR or ITC for purified-target binding confirmation.
Functional assays for biological validation.

For difficult target or site-discovery projects, Ligandability Mapping may also be useful.

Literature-Supported Case: Proteome-Scale Covalent Inhibitor Kinetics and Off-Target Profiling

Background

Covalent inhibitors are increasingly important in drug discovery, but their development requires careful balancing of potency and selectivity. A reactive warhead can support durable target engagement, but excessive or poorly controlled reactivity can increase off-target labeling across the proteome.

Lin and colleagues addressed this challenge in COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale. The study introduced COOKIE-Pro, a proteomics workflow designed to quantify irreversible covalent inhibitor binding kinetics and selectivity across the proteome.

Methods

The study used a two-step covalent occupancy kinetics enrichment strategy. In the first step, permeabilized cells were preincubated with a covalent inhibitor at defined concentrations and time points. In the second step, a desthiobiotin probe was used to enrich unoccupied target and off-target proteins. The enriched proteins were then analyzed by mass spectrometry-based proteomics.

The authors used BTK inhibitors, including spebrutinib and ibrutinib, to validate the approach. They also used controls such as DMSO and saturating inhibitor conditions to support occupancy interpretation. TMT-based quantification helped compare treatment groups and reduce injection-to-injection variation.

Results

The paper reported that COOKIE-Pro could profile covalent inhibitor binding kinetics and selectivity on the proteome scale. In the abstract, the authors state that the method reproduced known kinetic parameters for BTK inhibitors and identified both expected and unreported off-targets. They also reported that spebrutinib showed more than 10-fold higher potency for TEC kinase compared with its intended target BTK.

Figure 3 focuses on COOKIE-Pro profiling for spebrutinib in Ramos cells using the SB-2 desthiobiotin probe. It includes the spebrutinib and SB-2 probe structures, the experiment layout, a ranked proteomics off-target list, kinase off-target heatmaps, and kinetic fitting for BTK and TEC. In this case, the figure helps show how a covalent inhibitor profiling workflow can move from compound treatment to off-target ranking and kinetic interpretation.

The same study also applied a streamlined two-point strategy to a library of 16 covalent fragments. This generated thousands of kinetic profiles and supported quantitative separation of intrinsic chemical reactivity from binding affinity at scale.

Conclusion

This case shows why covalent inhibitor profiling should not rely only on single-target potency. A useful profiling workflow should connect target engagement, off-target ranking, concentration or time behavior, and data interpretation. For discovery teams, the value is not only identifying whether a compound works, but understanding how selectively it works across the proteome and which findings should guide the next round of chemistry or validation.

COOKIE-Pro covalent inhibitor profiling results showing spebrutinib target and off-target analysis with BTK and TEC kinetic fitting.

Figure 3 from Lin et al. shows COOKIE-Pro profiling of spebrutinib in Ramos cells, including ranked off-target proteomics, kinase off-target heatmaps, and kinetic fitting for BTK and TEC.

FAQ

Frequently Asked Questions

Q: What is covalent inhibitor selectivity profiling?

Covalent inhibitor selectivity profiling is an LC-MS/MS-based chemoproteomics approach used to evaluate how a covalent inhibitor engages target and off-target proteins across a defined biological sample or protein space. It helps assess selectivity, off-target burden, and compound prioritization.

Q: How does this service differ from standard potency testing?

Standard potency testing usually focuses on one target or assay readout. Covalent inhibitor selectivity profiling looks across a broader proteome or probe-accessible protein space to help show whether the compound is selective or broadly reactive.

Q: Can you evaluate target engagement and off-target risk in the same project?

Yes, when the workflow is designed appropriately. A profiling project can compare intended target engagement with off-target signals across compounds, concentrations, or analog series.

Q: When should I choose competitive ABPP for covalent inhibitor profiling?

Competitive ABPP is a good fit when a relevant activity-based probe is available and the key question is whether the inhibitor competes for probe-accessible proteins or sites. It is especially useful for target engagement, selectivity, and analog comparison.

Q: Can you compare analog series?

Yes. Analog series comparison is one of the most useful applications of covalent inhibitor profiling. It can help compare engagement strength, selectivity, off-target burden, and follow-up priority across related compounds.

Q: What sample types are compatible?

Common project formats include live cells, cell lysates, tissue lysates, compound or analog series, probes, and clickable analogs. Final feasibility depends on the profiling strategy, available material, compound properties, and biological question.

Q: Can the workflow provide residue-level evidence?

Residue- or peptide-level evidence may be available when the probe strategy, enrichment chemistry, peptide coverage, and LC-MS/MS depth support it. We review this expectation during project design and report it clearly in the final interpretation.

Q: What data deliverables will we receive?

Typical deliverables may include raw LC-MS/MS files, search result files, quantified protein tables, peptide or site evidence where applicable, ranked target/off-target lists, selectivity heatmaps, QC summaries, methods notes, and visualization-ready figures.

Q: How do you reduce false positives from nonspecific labeling?

We use control design, replicate review, probe or enrichment controls, background filtering, off-target burden review, and QC summaries to help distinguish stronger engagement patterns from weak or nonspecific signals.

Q: How should we choose between live-cell and lysate profiling?

Choose live-cell profiling when cellular context, permeability, and intact-cell target engagement matter. Choose lysate profiling when controlled proteome access, compound comparison, and early target-space exploration are more important.

References

Compliance Disclaimer

This service is provided for Research Use Only.

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.